|
|
|
|
|
| Barbosa,S.C.M.; Pereira,V.B.M.; Wong,D.V.T.; Santana,A.P.M.; Lucetti,L.T.; Carvalho,L.L.; Barbosa,C.R.N.; Callado,R.B.; Silva,C.A.A.; Lopes,C.D.H.; Brito,G.A.C.; Alencar,N.M.N.; Lima-Júnior,R.C.P.. |
| Oral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) and radiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable. Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy and chemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model of OM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the right cheek pouch; 5-FU (60 and 40 mg/kg, ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg) + 5-FU + scratches.... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Cancer chemotherapy toxicity; Oral mucositis; 5-Fluorouracil; Amifostine; Cytokines. |
| Ano: 2019 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000300601 |
| |
|
|
| De Souza,C.A.; Santini,G.; Marino,G.; Nati,S.; Congiu,A.M.; Vigorito,A.C.; Damasio,E.. |
| Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II study using amifostine as a protective drug against high-dose cyclophosphamide (HDCY) (7 g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and to reduce tumor burden. We enrolled 29 patients, 22 (75.9%) affected by aggressive and 7... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Amifostine; Cytoprotection; Non-Hodgkin's lymphoma; High-dose cyclophosphamide; Peripheral blood progenitor cell mobilization. |
| Ano: 2000 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2000000700009 |
| |
|
| |
|
|
|
